Phreesia, Inc. (NYSE:PHR – Get Free Report) COO Evan Roberts sold 2,029 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $22.86, for a total transaction of $46,382.94. Following the completion of the transaction, the chief operating officer now directly owns 754,903 shares of the company’s stock, valued at approximately $17,257,082.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Evan Roberts also recently made the following trade(s):
- On Monday, April 8th, Evan Roberts sold 7,178 shares of Phreesia stock. The shares were sold at an average price of $22.62, for a total value of $162,366.36.
- On Thursday, March 21st, Evan Roberts sold 25,962 shares of Phreesia stock. The stock was sold at an average price of $23.52, for a total transaction of $610,626.24.
Phreesia Trading Up 0.7 %
Phreesia stock opened at $23.16 on Thursday. The firm has a market cap of $1.31 billion, a PE ratio of -9.19 and a beta of 0.92. Phreesia, Inc. has a 12 month low of $12.05 and a 12 month high of $34.98. The stock’s 50 day simple moving average is $24.49 and its two-hundred day simple moving average is $21.25. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.02.
Analyst Upgrades and Downgrades
PHR has been the subject of a number of recent analyst reports. Stephens reissued an “overweight” rating and issued a $28.00 price objective on shares of Phreesia in a research report on Friday, March 22nd. Raymond James reiterated an “outperform” rating and set a $30.00 price objective (up from $25.00) on shares of Phreesia in a research note on Friday, March 15th. Canaccord Genuity Group raised their target price on Phreesia from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Friday, March 15th. Finally, Robert W. Baird raised their price objective on Phreesia from $30.00 to $31.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.62.
View Our Latest Stock Analysis on Phreesia
Institutional Trading of Phreesia
Institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in Phreesia during the first quarter worth $43,000. Captrust Financial Advisors lifted its holdings in Phreesia by 154.6% in the 2nd quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock valued at $36,000 after purchasing an additional 866 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Phreesia by 1,987.3% during the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock worth $34,000 after purchasing an additional 1,411 shares during the last quarter. State of Wyoming grew its holdings in shares of Phreesia by 34.6% during the second quarter. State of Wyoming now owns 1,918 shares of the company’s stock worth $59,000 after buying an additional 493 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Phreesia by 85.4% in the third quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock valued at $80,000 after buying an additional 1,445 shares during the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- United Airlines Soars on Earnings Beat
- Why Are Stock Sectors Important to Successful Investing?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Quiet Period Expirations Explained
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.